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Abstract: COVID-19 disease is associated with a high inflammatory load that can induce vascular inflammation, 
myocarditis, and cardiac arrhythmias. Mortality from COVID-19 disease in 2019 is strongly associated with 
cardiovascular disease, diabetes, and hypertension. These disorders share the underlying pathophysiology related 
to the renin-angiotensin system (SARS). Cardiovascular disease and SARS pharmacological inhibition increase ACE2 
levels, which can increase coronavirus virulence in the lung and heart. On the other hand, there is evidence that 
coronavirus infection can decrease ACE2, leading to toxic over-accumulation of angiotensin II, which induces acute 
respiratory distress syndrome and fulminant myocarditis. In addition, there is scientific evidence that SARS-CoV-2 
can bind chemically to the heme group of hemoglobin and thus cause the release of iron ions (Fe2+ and Fe3+) that 
can damage tissues, including the lungs and heart. Another important information is that the heme group is 
produced by mitochondria and, in this case, the oral or intramuscular use of Coenzyme Q10 (ubiquinone) is 
strongly recommended, as it stimulates the increase in mitochondrial production. Therefore, the use of chelators of 
iron ions is notorious, as well as the administration of Coenzyme Q10 as a treatment for patients infected with 
SARS-CoV-2. 
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Cardiovascular Disease /Angiotensin-
Converting enzyme / Angiotensin II 
Receptor Blockers and COVID-19: Major 
Approaches 
 A Coronavirus Disease (COVID-19) epidemic 
began in December 2019 in China, leading to a Public 
Health Emergency of International Interest. Clinical, 
laboratory and imaging characteristics have been 
partially characterized in some observational studies. 
Thus, it is necessary to assess the cardiovascular 
damage of patients with COVID-19 and to determine 
the correlation of the pro-terminal type B serum 
natriuretic peptide (NT-proBNP) and cardiac troponin I 
(cTnI) with the COVID-19 severity. Thus, a cross-
sectional study was carried out on 150 consecutive 
patients with COVID-19 at the fever clinic at Tongji 
Hospital in Wuhan, from January to February 2020, 
including 126 mild cases and 24 cases in intensive 
care. Univariate and multivariate logistic regression 
was used to analyze the correlation of past medical 
history, including hypertension, diabetes and Coronary 
Heart Disease (CHD), as well as serum levels of NT-
proBNP and cTnI in disease severity in patients with 
COVID-19. Age, hypersensitive C-reactive protein (hs-
CRP) and patients' serum creatinine levels were higher 
in intensive care than in mild cases (p<0.05). The 
prevalence of elevated male NT-proBNP and cTnI, 
hypertension and coronary heart disease was 
significantly higher in critical care patients than in mild 
cases (p<0.05). The univariate logistic regression 
analysis showed that age, male gender, elevated NT-
proBNP, elevated cTnI, elevated CRP, elevated serum 
creatinine, hypertension and CHD were significantly 
correlated with critical disease status (all p <0.05). 
Multivariate logistic regression analysis showed that 
high cTnI (OR = 26.909, 95% CI 4,086-177,226, P = 
0.001) and CHD (OR = 16,609, 95% CI 2,288-
120,577, P = 0.005) were the independent risk factors 
critical illness status. Thus, COVID-19 can significantly 
affect cardiac function and lead to myocardial injury. 
The past medical history of CHD and the increase in 
the level of cTnI are two independent determinants of 
SHORT REVIEW  
MedNEXT J Med Health Sci 2(1) (2021) 31-34 
 Vol 2 Iss 1 Year 2021                            M.C.V.B. Braile-Sternieri et al.,/2021           
 
Page 32 of 34 
the clinical status of the disease in patients with 
COVID-19 [1]. 
In addition, another study explored the clinical 
characteristics and prognosis of new patients with 
COVID-19 combined with cardiovascular disease 
(CVD). A retrospective analysis was performed on 112 
COVID-19 patients with CVD admitted to the western 
district of Union Hospital in Wuhan, from January 20, 
2020, to February 15, 2020. They were divided into a 
critical group (n = 16) and general group (n=96) 
according to the severity of the disease and the 
patients were followed up until the clinical outcome. 
Observation indicators included blood count, C-reactive 
protein (CRP), arterial blood gas analysis, myocardial 
injury markers, coagulation function, liver and kidney 
function, electrolyte, procalcitonin (PCT), type B 
natriuretic peptide (BNP), blood lipids, pulmonary CT 
and pathogen detection. Compared with the general 
group, the lymphocyte count was extremely lower in 
the critical group, CRP (106.98 (81.57, 135.76) mg / L 
vs. 34.34 (9.55.76.54) mg / L, p <0.001) and PCT 
(0.20 (0.15.0.48) µg / L vs. 0.11 (0.06.0.20) µg / L, p 
<0.001) were significantly higher in critical group. The 
BMI of the critical group was significantly higher than 
that of the general group (25.5 (23.0, 27.5) kg/m2 vs. 
22.0 (20.0, 24.0) kg/m2, p = 0.003). Patients were 
divided into a non-surviving group (17, 15.18%) and a 
surviving group (95, 84.82%). Among non-survivors, 
there were 88.24% (15/17) patients with BMI> 25 
kg/m2, which was significantly higher than that of 
survivors (18.95% (18/95), p<0.001). Compared with 
surviving patients, the oxygenation index (130 (102, 
415) vs. 434 (410, 444), p<0.001) was significantly 
lower and lactic acid (1.70 (1.30, 3.00) mmol/L vs. 
1.20 (1.10, 1.60) mmol/L, p<0.001) was significantly 
higher in non-survivors. Therefore, COVID-19 patients 
combined with CVD are associated with an increased 
risk of mortality. Critical patients are characterized by 
fewer lymphocytes. Higher BMI is more often seen in 
critically ill, non-survivors. The use of angiotensin 
converting enzyme inhibitor and angiotensin receptor 
blockers (ACEI and ARB) does not affect the morbidity 
and mortality of COVID-19 combined with CVD. 
Aggravating causes of death include fulminant 
inflammation, accumulation of lactic acid and 
thrombotic events [2]. 
Another study included patients with acute 
myocardial infarction with ST-segment elevation 
(STEMI) admitted by the Accident and Emergency 
Department and in whom the percutaneous coronary 
interventions (PCI) was performed in Wuhan-China. 
The focus spanned the period since January 25, 2020, 
when city hospitals began instituting emergency 
infection protocols to contain COVID-19. This required 
hospitals to suspend all non-essential visits and adjust 
internal and external clinical services. PCI nominations 
were in accordance with international guidelines. The 
criteria included hospitalized STEMI (n=1), STEMI with 
unknown onset of symptoms (n=3) and patients with 
cardiac arrest (n=2). The time between the onset of 
the symptom and the first medical contact is defined 
as the time from the beginning of the chest discomfort 
reported by the patient until the moment of the first 
medical contact. The door-to-device time is defined as 
the time of arrival from the Accident and Emergency 
Department until the cable runs successfully during 
PCI. The time of arrival at the catheterization device is 
defined as the time between the patient's arrival at the 
catheterization laboratory and the time that the wire 
passes successfully. From January 25, 2020, to 
February 10, 2020, we observed changes in the 
temporal components of treatment with STEMI among 
the aggregate group of 7 consecutive patients 
undergoing PCI. They were compared with data from 
108 patients with STEMI treated with PCI in the 
previous year, from February 1, 2018, to January 31, 
2019 (n = 108). These 7 patients did not suffer from 
COVID-19 infection and 6 out of 7 went to our hospital 
during regular work hours [3]. 
In addition, cardiovascular metabolic 
comorbidities made patients more susceptible to 
COVID-19 and exacerbated the infection. Thus, a 
study analyzed the association of cardiovascular 
metabolic diseases with the development of COVID-19. 
A meta-analysis of eligible studies was performed that 
summarized the prevalence of cardiovascular metabolic 
diseases in COVID-19 and compared the incidences of 
comorbidities in Intensive Care Units (ICU)/critically ill 
and non-ICU/critically ill patients. A total of six studies 
with 1527 patients were included in this analysis. The 
proportions of hypertension, cardio-cerebrovascular 
disease, and diabetes in patients with COVID-19 were 
17.1%, 16.4%, and 9.7%, respectively. The incidences 
of hypertension, cardio-cerebrovascular diseases and 
diabetes were two to three times and twice, 
respectively, higher in ICU/severe cases than in non-
ICU/severe patients. At least 8.0% of patients with 
COVID-19 suffered the acute cardiac injury. The 
incidence of acute cardiac injury was about 13 times 
higher in the ICU/critically ill patients compared to 
non-ICU/critically ill patients. Patients with previous 
cardiovascular metabolic diseases may face an 
increased risk of progressing to a serious condition and 
comorbidities can also greatly affect the prognosis of 
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COVID-19. Therefore, COVID-19 can aggravate 
damage to the heart [4]. 
Also, a systematic literature review was carried 
out with meta-analysis, using three databases to 
evaluate clinical, laboratory, imaging and results of 
cases confirmed with COVID-19. Observational studies 
and also case reports were included and analyzed 
separately. Was performed a meta-analysis of the 
random-effects model to calculate the combined 
prevalence and 95% confidence interval (95% CI). 660 
articles were recovered for the period (1/1/2020 to 
2/23/2020). After screening, 27 articles were selected 
for evaluation in full text, 19 were finally included for 
qualitative and quantitative analyzes. In addition, 39 
case report articles were included and analyzed 
separately. For 656 patients, fever (88.7%, 95% CI 
84.5-92.9%), cough (57.6%, 40.8-74.4%) and 
dyspnea (45.6%, 10.9 -80.4%) were the most 
prevalent manifestations. Among the patients, 20.3% 
(95% CI 10.0-30.6%) required an ICU, 32.8% had 
acute respiratory distress syndrome (ARDS) (95% CI 
13.7- 51.8), 6.2% (95% CI 3.1 -9.3) with shock. 
Approximately 13.9% (95% CI 6.2-21.5%) of 
hospitalized patients had fatal results. COVID-19 
places an enormous burden on health services, 
especially in patients with comorbidities. The ICU was 
necessary for approximately 20% of polymorphic 
patients infected with COVID-19 and hospitalization 
was associated with a fatal results above 13% [5].  
Therefore, patients with COVID-19 combined 
with cardiovascular disease are associated with an 
increased risk of mortality. Critical patients are 
characterized by fewer lymphocytes. Higher BMI is 
more often seen in critically ill, non-survivors. The use 
of ACEI/ARB does not affect the morbidity and 
mortality of COVID-19 combined with CVD. 
Aggravating causes of death include fulminant 
inflammation, accumulation of lactic acid and 
thrombotic events. Therefore, cardiovascular metabolic 
comorbidities made patients more susceptible to 
COVID-19 and exacerbated the infection [5]. 
COVID-19 disease is associated with a high 
inflammatory load that can induce vascular 
inflammation, myocarditis, and cardiac arrhythmias. 
Thus, cardiovascular risk factors and conditions must 
be carefully controlled according to the evidence-based 
guidelines [6]. Mortality is strongly associated with 
cardiovascular disease, diabetes, and hypertension. 
These disorders share the underlying pathophysiology 
related to the renin-angiotensin system (SARS) which 
can be clinically illuminating. In particular, the activity 
of the angiotensin-converting enzyme 2 (ACE2) is 
unregulated in cardiovascular diseases, and this 
enzyme is used by the coronavirus to initiate infection 
[6]. 
Cardiovascular disease and SARS 
pharmacological inhibition increase ACE2 levels, which 
can increase coronavirus virulence in the lung and 
heart [7]. On the other hand, there is evidence that 
coronavirus infection can decrease ACE2, leading to 
toxic over-accumulation of angiotensin II, which 
induces acute respiratory distress syndrome and 
fulminant myocarditis. Inhibition of SARS can reduce 
this effect [7]. 
In addition, there is scientific evidence that 
SARS-CoV-2 can chemically bond to the heme group of 
hemoglobin and thus cause the release of iron ions 
(Fe2+ and Fe3+) that can damage tissues, including the 
lungs and heart [8]. Another important information is 
that the heme group is produced by mitochondria and, 
in this case, the oral or intramuscular use of Coenzyme 
Q10 (ubiquinone) is strongly recommended, as it 
stimulates the increase in mitochondrial production 
[9,10]. Therefore, the use of chelators of iron ions is 
notorious, as well as the administration of Coenzyme 




Dysfunction of the renin-angiotensin system 
(SARS) has been observed in patients infected with 
coronavirus (COVID-19). However, SARS inhibitors, 
such as ACEI inhibitors and ARB, are associated with a 
lower rate of serious illnesses and a tendency to 
reduce the level of IL-6 in peripheral blood. Also, 
therapy with ACEI or BRA increased the CD3 and CD8 
T cell counts in peripheral blood and decreased the 
peak viral load compared to other antihypertensives. 
This evidence supports the benefit of using ACE 
inhibitors or ARBs to potentially contribute to 
improving the clinical outcomes of patients with 
systemic arterial hypertension. Based on currently 
available evidence, treatment with renin-angiotensin 
system blockers should not be interrupted due to 
concerns about coronavirus infection. 
 
References 
[1] C. Chen, C. Chen, J.T. Yan, N. Zhou, J.P. Zhao, 
D.W. Wang, Analysis of myocardial injury in 
patients with COVID-19 and association between 
concomitant cardiovascular diseases and severity 
of COVID-19. Zhonghua Xin Xue Guan Bing Za 
MedNEXT J Med Health Sci 2(1) (2021) 31-34 
 Vol 2 Iss 1 Year 2021                            M.C.V.B. Braile-Sternieri et al.,/2021           
 
Page 34 of 34 
Zhi, 48(7) (2020) 567-571. DOI | PubMed   
[2] Y.D. Peng, K. Meng, H.Q. Guan, L. Leng, R.R. 
Zhu, B.Y. Wang, M.A. He, L.X. Cheng, K. Huang, 
Q.T. Zeng, Clinical characteristics and outcomes 
of 112 cardiovascular disease patients infected 
by 2019-nCoV, Zhonghua Xin Xue Guan Bing Za 
Zhi, 48(6) (2020)450-455. DOI | PubMed  
[3] C.F. Tam, K.S. Cheung, S. Lam, A. Wong, A. 
Yung, M. Sze, Y.M. Lam, C. Chan, T.C. Tsang, M. 
Tsui, H.F. Tse, CW. Siu, Impact of Coronavirus 
Disease 2019 (COVID-19) Outbreak on ST-
Segment-Elevation Myocardial Infarction Care in 
Hong Kong, China, Circulationa. Cardiovascular 
Quality and Outcomes, 13(4) (2020) e006631. 
DOI | PubMed  
[4] B. Li, J. Yang, F. Zhao, L. Zhi, X. Wang, L. Liu, Z. 
Bi, Y. Zhao, Prevalence and impact of 
cardiovascular metabolic diseases on COVID-19 
in China, Clinical Research in Cardiology, 109(5) 
(2020) 531-538. DOI | PubMed 
[5] A.J. Rodriguez-Morales, J.A. Cardona-Ospina, E. 
Gutiérrez-Ocampo, R. Villamizar-Peña, Y. 
Holguin-Rivera, J.P. Escalera-Antezana, L.E. 
Alvarado-Arnez, D.K. Bonilla-Aldana, C. Franco-
Paredes, A.F. Henao-Martinez, A. Paniz-Mondolfi, 
G.J. Lagos-Grisales, E. Ramírez-Vallejo, J.A. 
Suárez, L.I. Zambrano, W.E. Villamil-Gómez, G.J. 
Balbin-Ramon, A.A. Rabaan, H. Harapan, K. 
Dhama, H. Nishiura, H. Kataoka, T. Ahmad, R. 
Sah, Latin American Network of Coronavirus 
Disease 2019-COVID-19 Research (LANCOVID-
19). Clinical, laboratory and imaging features of 
COVID-19: A systematic review and meta-
analysis. Travel Medicine and Infectious Disease, 
(2020) 101623. DOI | PubMed  
[6] M. Madjid, P. Safavi-Naeini, S.D. Solomon, O. 
Vardeny, Potential Effects of Coronaviruses on 
the Cardiovascular System: A Review, JAMA 
Cardiology, 5(7) (2020) 831-840. DOI | PubMed  
[7] T.C. Hanff, M.O. Harhay, T.S. Brown, J.B. Cohen, 
A.M. Mohareb, Is There an Association Between 
COVID-19 Mortality and the Renin-Angiotensin 
System-a Call for Epidemiologic Investigations, 
Clinical Infectious Diseases, 71(15) (2020) 870-
874. DOI | PubMed 
[8] liu Wenzhong, Li hualan, COVID-19: Attacks the 
1-Beta Chain of Hemoglobin and Captures the 
Porphyrin to Inhibit Human Heme Metabolism, 
ChemRxiv. Preprint. (2020). DOI  
[9] Viruna Neergheen, Annapurna Chalasani, Luke 
Wainwright, Delia Yubero, Raquel Montero, 
Rafael Artuch, Iain Hargreaves, Coenzyme Q10 
in the Treatment of Mitochondrial Disease, 
Journal of Inborn Errors of Metabolism and 
Screening, 5 (2017) 1-8.  DOI  
[10] I.L. Bocalon, M.H.V. Marques, I.J.Z. Filho, 
Approaches to the Potential Use of Stromal 
Vascular Fraction and Coenzyme Q10 in 
Dermatological Aesthetics: A Systematic Review, 
Journal of Dermatology Research and Theraphy, 















We would like to thank financial support of Domingo 
Braile Institute of São José do Rio Preto/SP 
 
Authors Contribution 
Data collection, analysis and preparation of initial draft 
(MCVBB-S, VRRF, EMM, SBS, GBS, LBV, COVQ & 
BCS); Designing the study, data collection, analysis, 
preparation and finalizing the manuscript (IJZF). 
   
Data sharing statement 
No additional data are available  
 
Ethics Approval  
Not Applicable    
 
Informed consent 
Not Applicable    
 
Conflict of interest  
The authors declare no conflict of interest. 
 
About The License 
© The author(s) 2020. The text of this article is open 
access and licensed under a Creative Commons 
Attribution 4.0 International License 
 
